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OBJECTIVES: Gastroesophageal reflux is common in patients post-lung transplantation (LTx) and thus considered a risk factor for
aspiration and consequently allograft rejection and the development of chronic allograft failure. However, evidence supporting this
remains unclear and often contradictory. Our aim was to examine the role played by esophageal motility on gastroesophageal
reflux exposure, along with its clearance and that of boluses swallowed, and the relationship to development of obstructive
chronic lung allograft dysfunction (o-CLAD).
METHODS: Patients post-LTx (n= 50, 26 female; mean age 55 years (range, 20–73 years)) completed high-resolution impedance
manometry and 24-h pH/impedance. Esophageal motility abnormalities were classified based upon the Chicago Classification
version 3.0.
RESULTS: Esophagogastric junction outflow obstruction alone (EGJOOa) (P= 0.01), incomplete bolus transit (IBT) (P= 0.006)
and proximal reflux (P= 0.042) increased the risk for o-CLAD. Patients with EGJOOa were most likely to present with o-CLAD
(77%); despite being less likely to exhibit abnormal numbers of reflux events (10%) compared with those with normal motility
(o-CLAD: 29%, Po0.05; abnormal reflux events: 64%, Po0.05). Patients with EGJOOa had lower total reflux bolus exposure time
than those with normal motility (0.6 vs. 1.5%; Po0.05). In addition, poor esophageal clearance documented by abnormal
post-reflux swallow-induced peristaltic wave index associated with o-CLAD; inversely correlating with the proportion of reflux
events reaching the proximal esophagus (r=− 0.251; P= 0.052).
CONCLUSIONS: These observations support esophageal dysmotility, especially EGJOOa, and impaired clearance of swallowed
bolus or refluxed contents, more so than just the presence of gastroesophageal reflux alone, as important risk factors in the
development of o-CLAD.
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INTRODUCTION
Aspiration of gastric contents is considered a non-alloimmune
cause for the development of chronic graft failure following lung
transplantation (LTx). Despite the high prevalence of gastro-
esophageal reflux disease (GERD) in patients post-LTx1–7
and some data that support GERD as a risk factor for
rejection,2,4–6,8–11 other studies have not demonstrated an
association between reflux severity and bronchiolitis obliterans
syndrome (BOS),1,3,7 or correlation between FEV1 and reflux
or bronchoalveolar lavage fluid (BALF) pepsin/bile acid
concentrations,1 suggesting that other factors must be involved
in the development of chronic graft failure.
Esophageal dysmotility has been shown to associate with
prolonged reflux clearance times and higher reflux exposure
time, and indeed slower passage of “swallowed” boluses in
patients with GERD12 and chronic cough.13 However,
although esophageal dysmotility has been shown in patients
following LTx,6,7,14–17 its relationship to gastroesophageal
reflux (GER) and/or swallowed bolus clearance, and thus the
possibility of aspiration and/or obstructive chronic lung
allograft dysfunction (o-CLAD) remains unclear. This lack of
clarity may be related to the diagnostic limitations associated
with the older low-resolution catheters and conventional
manometry parameters used in these studies, as although
some studies did use high-resolution esophageal impedance
manometry (HRIM),14–16 no study used the Chicago
Classification (CC), the most current classification of esopha-
geal motor disorders, to define motility post-LTx. Moreover,
only one study has compared dysmotility (again using
conventional parameters) and GERD prevalence in LTx
patients with and without allograft dysfunction, which reported
no difference.7 Lastly, all but one6 of the previous studies
reporting on both motility and GER used pH alone without
concurrent impedance, which might have resulted in under-
estimation of GER.
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The aim of this study was therefore to use HRIM along with
pH/impedance for the first time to determine the prevalence of
dysmotility using the CC and assess its impact on both
swallowed and reflux bolus clearance and thus exposure of
the esophagus to excessive luminal content and subsequent
development of o-CLAD in patients post-LTx.
METHODS
Patients. Consecutive post-LTx patients (n= 50, 26 female;
mean age 55 (range, 20–73) years) referred for HRIM and
pH/impedance approximately 3 months after surgery at Mayo
Clinic, Florida between October 2012 and December 2014
with follow-up through 31 July 2015 were included. Patient
data included age, sex, body mass index, donor and recipient
cytomegalovirus immune status, indication for LTx, LTx date,
intra-operative data, post-LTx medication, post-LTx complica-
tions, including acute rejection, o-CLAD and death. The Mayo
Clinic Institutional Review Board approved the study.
HRIM. HRIM was performed using a solid state catheter with
36 circumferential pressure sensors spaced at 1 cm intervals
and 18 impedance channels (Medtronic, Shoreview, MN).
The catheter was positioned transnasally with the distal
sensors for both pressure and impedance in the proximal
stomach. Following at least a 30 s baseline to identify the
upper esophageal sphincter (UES) and LES, ten 5 ml saline
swallows were given at least 30 s apart with the patient
supine.13
pH/impedance. pH/impedance (Sandhill Scientific, High-
lands Ranch, CO) was performed using a single antimony
pH probe (5 cm above the LES) with eight impedance
electrodes.13
Diagnosis of o-CLAD. The term CLAD includes the entities
of BOS and restrictive allograft syndrome, the former being
characterized by obstruction and the latter by a restrictive
component.18,19 To date, all studies reporting on the possible
link between reflux, aspiration and lung allograft dysfunction
have concentrated on BOS. To our knowledge, there is no
established link between reflux and restrictive allograft
syndrome.18,19 As such, we have focused specifically on
“obstructive CLAD”,19 defined per the joint ATS/ERS state-
ment on BOS, including BOS 0-p.20
Data analysis
HRIM. ManoVIEW Analysis software v3.01 (Medtronic,
Shoreview, MN) was used to manually analyze the record-
ings. Esophageal motility was classified based upon
CC 3.0.21 Each 5 ml swallow was evaluated to determine:
(i) integrated relaxation pressure, (ii) distal contractile
integral, and (iii) distal latency.21 Contractile pattern was
classified as premature, fragmented, or intact.21
CC version 3.0 diagnoses included: (i) achalasia or EGJOO,
the latter defined as poor deglutitive relaxation of the LES
(median integrated relaxation pressure 415 mmHg), with
some instances of intact or weak peristalsis, not meeting the
criteria for achalasia; (ii) major disorders of peristalsis, such as
absent contractility, distal esophageal spasm, and hypercon-
tractile esophagus; or (iii) minor disorders of peristalsis, such
as ineffective esophageal motility, and fragmented
peristalsis.21
Impedance recordingswere evaluated for each swallow and
bolus clearance assessed using both colorized contour
functions and superimposed impedance tracings, as pre-
viously described.22 Bolus clearance was defined as “com-
plete” or “incomplete” based on the color overlay and line-
tracing modes.22 Subjects were classified as complete bolus
transit when clearance was seen in ≥80% of swallows.23
24-h pH/impedance. BioVIEW analysis software (Sandhill
Scientific) was used to identify reflux episodes based on
retrograde impedance decrease to 50% of baseline in at least
two distal adjacent channels. Meal periods were excluded. In
patients off proton pump inhibitors (PPI) 473 episodes was
considered abnormal;24 448 episodes on b.i.d. PPI.25
Proximal reflux events were defined as those that reached
at least 15 cm above LES (normal ≤31 off PPI, ≤ 19 on
PPI).24,25 Since data on abnormal reflux frequency on q.d.
PPI are not available, we classified those patients with ≤ 48
reflux events as normal and those with 473 episodes as
abnormal. For proximal reflux events, we defined patients on
q.d. PPI with ≤19 reflux events as normal and those with
431 episodes as abnormal (only three patients could not be
classified and were excluded from any categorical analysis).
Bolus clearance time was defined as lapsed time that the
bolus was present at each impedance level during a specific
reflux episode or time interval between bolus entry and
clearance. Total reflux bolus exposure time was the percen-
tage of monitored time that the esophagus was exposed to
reflux of any nature.
Acid exposure time was defined as the percentage of total
time that pH was below 4 at the distal sensor (normal values
o4.2 off PPI oro1.6 on PPI).25,26
Post-reflux swallow-induced peristaltic wave (PSPW) index.
The PSPW index, a novel measure of esophageal clearance
in pH/impedance studies, is defined as the number of reflux
episodes followed by an impedance-detected swallow occur-
ring within 30 s of the end of the reflux episode, divided by the
total number of reflux episodes.27,28 The PSPW index was
considered abnormal if o61%.28
Statistics. Group differences were evaluated using Stu-
dent’s t-tests or Mann–Whitney U-tests. Associations were
assessed using χ2 or Fisher’s exact tests. Univariate log-rank
tests and Kaplan–Meier plots were used to evaluate
cumulative hazards for o-CLAD. Cox proportional hazards
regression was used to estimate hazard ratios (HR) and 95%
confidence intervals for the associations between time to
o-CLAD and incomplete bolus transit, EGJOO alone
(EGJOOa), (i.e., achalasia or esophagogastric junction out-
flow obstruction, without concomitant hypercontractile peri-
stalsis, see above) and, proximal and distal reflux frequency
exceeding the upper limit of normal, and acute rejection after
controlling for potential confounders from univariate compar-
isons with Po0.100. Cox proportional hazards were com-
pleted controlling for length of time between LTx and
esophageal testing. Significance was evaluated at the
two-tailed, Po0.05 levels.
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RESULTS
Primary indications for LTx were diffuse parenchymal lung
diseases (52%; 92% IPF and 8% other interstitial lung
disease) and COPD (28%). Thirty-three patients (66%)
underwent bilateral and 15 patients (30%) unilateral LTx (two
underwent re-transplant). HRIM was completed a median
(IQR) of 91 days (83–409) from LTx in 50 patients. Of these, 45
(90%) underwent combined pH/impedance monitoring, with
35 (78%) of these being completed on PPI (19 b.i.d, 16 q.d)
and 10 (22%) off PPI. Following HRIM and pH/impedance
testing, 47 (94%) patients were on PPI (26 b.i.d, 21 q.d). Four
(8%) patients underwent anti-reflux surgery (three laparo-
scopic Nissen fundoplication, one implanted LINX) after
HRIM. Median (IQR) post-LTx follow-up was 909 days
(637–1,107).
Acute rejection (acute cellular rejection and/or lymphocytic
bronchiolitis) was found in 32/50 (64%) patients a median
(IQR) of 59 days (29–334) day after LTx, 23 (46%) developed
o-CLAD 725 (495–1,117) days after LTx, and 4 (8%) died
1,677 (870–2193) days after LTx (all had o-CLAD).
o-CLAD vs. without o-CLAD. Table 1 shows the character-
istics of LTx patients with and without o-CLAD. There was no
significant difference between any of the variables, except for
more deaths in patients with o-CLAD (P= 0.038). Critically,
the median (IQR) time from transplant to the last follow-up of
patients with no o-CLAD (726 (565–1,010) days) was not
different from the time to o-CLAD in those with o-CLAD (725
(495–1,117) days; P= 0.793), indicating that the presence of
o-CLAD was not related to longer time since LTx.
HRIM (CC v3.0). Patients with o-CLAD were more likely to
exhibit EGJOOa (i.e., achalasia or EGJ outflow obstruction)
than patients without o-CLAD (P= 0.011). Removal of the four
patients with achalasia did not affect these findings (35% vs.
8%; P=0.026) There were no differences in the rates of all
other CC diagnoses for patients with vs. without o-CLAD
(Table 2). While distal latency was shorter (P=0.032) in
patients with o-CLAD, all values were within the normal range.
Bolus transit. Both the proportion of patients with IBT (83% vs.
33%;P= 0.001) and percentage of swallowswith IBT (50% vs.
10%;P= 0.002) were higher in patientswith o-CLAD (Table 2).
24-h pH/impedance. Reflux parameters were not different
between patients with and without o-CLAD; though those with
o-CLAD tended to have more reflux events (proximal,
P= 0.139; distal, P=0.184) and be classified as having
abnormal levels of reflux (total, P=0.134; proximal,
P= 0.082) (Table 3).
PSPW index. Patients with o-CLAD were more likely to have
an abnormal PSPW index than those without (83% vs 52%;
P= 0.034). PSPW index inversely correlated with the propor-
tion of reflux events reaching the proximal esophagus
(r=− 0.251; P=0.052) (Figure 1).
Time to event analysis. In univariate analyses, EGJOOa (HR,
2.91; 1.20–6.99; P= 0.018), IBT (HR, 3.93; 95% CI: 1.30–
11.86; P=0.015), acute rejection (HR, 2.73; 0.90–8.24;
P= 0.075), and proximal reflux (HR, 2.48; 0.97–6.29;
P= 0.057), but not PSPW, distal reflux, nor dose of PPI during
follow-up appeared associated with a higher risk for develop-
ing o-CLAD during follow-up.
EGJOOa (HR, 3.265; 1.332–8.007; P=0.01), IBT (HR,
4.815; 1.558–14.878; P= 0.006), and proximal reflux (HR,
2.666; 1.038–6.845; P=0.042) but not acute rejection
appeared to be predictors for the time to the development of
o-CLAD following multivariable Cox proportional hazards
regression controlling for length of time from LTx to HRIM
and pH/impedance.
Abnormal vs. normal motility. To further assess how
disordered motility may influence reflux, swallowed bolus
clearance and relationship with o-CLAD, patients were
categorized using CC v3.0 into those with (i) EGJOOa, (i.e.,
achalasia and esophagogastric junction outflow obstruction
without concomitant hypercontractile peristalsis), (ii) hyper-
contractility (Jackhammer, distal esophageal spasm), (iii)
EGJOO with hyper-contractility (EGJOOh), and (iv) hypo-
contractility (absent contractility, ineffective esophageal moti-
lity and fragmented peristalsis). EGJOOa (77%) (not other
subgroups) was significantly more likely to develop o-CLAD
Table 1 Comparison of general characteristics of LTx patients with and without
o-CLAD
o-CLAD (n= 23) Without
o-CLAD (n= 27)
P value
Age, yearsa 59 (57–64) 61 (40–65) 0.915
Female:Male ratio 9:14 17:10 0.081
Body mass index,
kg/m2 b
27.6 (25.4–29.8) 25.9 (24.1–27.6) 0.211
0.513
Indication for LTx,
n(%) c
0.513
DPLD 10 (44%) 16 (59%)
COPD 9 (39%) 5 (19%)
CF 1 (4%) 3 (11%)
PAH, idiopathic 1 (4%) 1 (4%)
PAH, CHD 0 1 (4%)
Sarcoidosis 1 (4%) 0
ReLTx 1 (4%) 1 (4%)
0.513
CMV status, n(%)c 0.258
D− /R− 5 (22%) 1 (4%)
D− /R+ 2 (9%) 2 (7%)
D+/R− 8 (35%) 11 (41%)
D+/R+ 8 (35%) 13 (48%)
0.513
LTx, n(%)c 0.244
Unilateral 9 (39%) 7 (26%)
Bilateral 14 (61%) 20 (74%)
0.513
Anti-reflux surgery,
n(%)c
1 (4%) 3 (11%) 0.380
0.513
Post-LTx complicationsc
Acute rejection,
n(%)
17 (74%) 15 (56%) 0.146
Death, n(%) 4 (17%) 0 0.038
CF, cystic fibrosis; CHD, congenital heart disease; CMV, cytomegalovirus;
COPD, chronic obstructive pulmonary disease; D, donor; DPLD, diffuse
parenchymal lung disease; LTx, lung transplantation; o-CLAD, obstructive
chronic lung allograft dysfunction; PAH, pulmonary arterial hypertension; R,
recipient.
aResults are expressed as either median (IQR).
bMean (95% CI).
cPercentage for categorical variables.
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compared with normal motility (P=0.016) (Table 4). This was
the case despite fewer patients with EGJOOa having
abnormal numbers of reflux events (10%) compared with
those with normal motility (64%; P=0.011). Patients with
hyper-contractility (20%) were similarly less likely to exhibit
an abnormal number of reflux events compared with those
with normal motility (P= 0.04). This was associated with a
shorter total reflux bolus exposure time in patients with
EGJOOa (P= 0.011) and EGJOOh (P=0.047) compared
with normal motility. Acid exposure time was not different
between the motility subgroups (Table 4).
Although patientswith hypo-motility (86%) hadmore swallows
associated with IBT compared with normal motility (57%,
P=0.094) this did not reach statistical significance (Table 4).
DISCUSSION
For the first time we have shown that EGJOOa, IBT, and
proximal reflux all increase the risk for the development of
o-CLAD post-LTx. Patients with o-CLAD were significantly
more likely to present with EGJOOa, incomplete transit of
boluses swallowed and an impaired reflux clearance docu-
mented by abnormal PSPW index than those without o-CLAD.
Moreover, although patients with o-CLAD appeared no more
likely to exhibit an abnormal number of reflux events than
those without o-CLAD, more patients with o-CLAD tended to
have abnormal numbers of reflux events reaching the proximal
esophagus (P= 0.082), possibly as a result of both IBTand a
lower PSPW index, which inversely correlated with the
proportion of reflux events reaching the proximal esophagus.
Notably, the development of o-CLAD in patients presenting
with EGJOOawas not associated with abnormal GER, as only
one patient (10%) exhibited abnormal levels of reflux
compared with 64% of those with normal motility. Contrary to
expectations, patients with hypo-contractility were no more
likely to have o-CLAD than those with normal motility. These
data suggest that poor clearance of boluses, be it swallowed or
reflux, may be more likely to aspirate into the airways,
especially when the EGJ is obstructed than just because of
the presence of abnormal reflux alone. These observations
therefore pose important questions regarding clinicians’
current focus on GER, particularly if only distal esophageal
reflux is considered and its potential association with
Table 2 Individual HRIM parameters, diagnostic classifications based on Chicago v3.0, and bolus transit findings in LTx patients with and without o-CLAD
o-CLAD (n= 23) Without o-CLAD (n= 27) P value
HRIM findings
UES resting pressure, mmHga 56.8 (46.3–88.3) 56.4 (47.0–76.2) 0.888
UES relaxation pressure, mmHga 3.2 (1.0–6.6) 1.7 (0.9–7.2) 0.410
LES resting pressure, mmHga 29.9 (27.4–42.9) 34.5 (28.9–48.0) 0.202
LES-CD separation,42 cm, n(%)b 2 (9%) 0 0.207
Mean IRP, mmHg (C, v2.0)a 13.1 (7.6–18.8) 11.3 (9.1–14.5) 0.436
Median IRP, mmHg (C, v3.0)a 12.9 (7.2–18.6) 11.0 (9.1–14.0) 0.386
CFV, cm/sa 4.6 (3.4–6.4) 3.2 (2.4–4.3) 0.002
DL, sa 6.2 (5.3–7.0) 7.4 (5.9–8.3) 0.032
DCI, mmHg/s/cma 1822.0 (1125.7–5048.8) 4313.4 (1847.6–8373.1) 0.062
Chicago v3.0, n(%)b
Normal 4 (17%) 10 (37%) 0.109
EGJOO alone 10 (44%) 3 (11%) 0.011
Hyper-contractility 4 (17%) 8 (30%) 0.251
EGJOO
With hyper-contractility 1 (4%) 3 (11%) 0.368
Hypo-contractility 4 (17%) 3 (11%) 0.407
Bolus transit findings
Patients with IBT, n(%)b 19 (83%) 9 (33%) 0.001
Swallows with IBT, %a 50 (30–100) 10 (0–40) 0.002
Time from LTx to HRIM, daysa 96 (87–1692) 89 (80–111) 0.020
CFV, contractile front velocity; DCI, distal contractile integral; DL, distal latency; EGJOO, esophagogastric junction outflow obstruction; IRP, integrated relaxation
pressure; LES, lower esophageal sphincter; LES-CD, LES to crural diaphragm distance; o-CLAD, obstructive chronic lung allograft dysfunction; UES, upper
esophageal sphincter.
aResults expressed as either median (IQR).
bPercentage for categorical variables.
Table 3 24-h pH/impedance in LTx patients with and without o-CLAD
o-CLAD
(n=20)
Without
o-CLAD
(n=25)
P
value
Total no. of events, na 57 (32–82) 39 (23–69) 0.184
Patients with abnormal no. of
events, n(%)b
9/19 (47%) 6/23 (26%) 0.134
Proximal events, n a 17 (6–34) 10 (5–16) 0.139
Patients with abnormal no. of
proximal events, n (%)b
8/20 (40%) 4/24 (17%) 0.082
Total reflux bolus exposure
time, %a
1.1 (0.4–2.3) 0.8 (0.5–1.7) 0.437
Bolus clearance time, sa 11 (8–16) 13 (10–16) 0.474
Acid exposure time, %a 0.9 (0.3–6.7) 2.2 (0.8–6.4) 0.314
o-CLAD, obstructive chronic lung allograft dysfunction.
Note that only 45 patients underwent 24-h pH/impedance, of which three
patients on once daily PPI could not be classified with respect to whether they
had an abnormal total number of reflux events and one patient with respect to
whether they had an abnormal number of proximal reflux events. These patients
were excluded from analysis.
aResults are expressed as either median (IQR).
bPercentage for categorical variables.
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aspiration post-LTx, and suggest that EGJOOa and poor
esophageal clearance may be very important for the devel-
opment of o-CLAD.
Our novel data therefore challenge the belief that GER, and
particularly its association with hypo-contractility patterns,
such as ineffective esophageal motility, is the main precursor
for the development of o-CLAD, and suggest that EGJOOa
and associated poor clearance of swallowed boluses may be
equally important for the development of o-CLAD. This does
not exclude the possibility of refluxate aspirating into the
airways, as suggested by proximal (but not distal) reflux
significantly predicting the development of o-CLAD and
supported by studies reporting the presence of pepsin
and/or bile acids in BALF in patients post-LTx.1–3,5,6,8,9,29
Moreover, some studies have reported that proximal reflux
events correlate with BALF neutrophils,6 with the latter
correlating with BALF bile acid concentrations, which might
shorten freedom from BOS.8 However, our findings help
explain why “not all” studies have shown that (i) distal reflux
and BALF pepsin/bile acid concentrations correlate with lung
function,1 (ii) distal reflux correlates with BALF pepsin
concentration, and is associated with a quicker progression to
BOS5 and (iii) fundoplication is associated with improved lung
function.30 Those patients that do respond well to fundoplica-
tion are likely those in whom GERD is an important mecha-
nism for rejection but currently there are no comprehensive
sham/placebo-controlled data (e.g., pre- and post-transplant
esophageal body and LES/UES motility, using CC, impe-
dance/pH data, BALF pepsin levels, and effect of surgery/type
of surgery; oropharyngeal function etc.) available to formally
explore which patients best benefit from fundoplication. Till
then, an individualized approach keeping these factors in mind
Figure 1 Pearson correlation of percentage of reflux events reaching the
proximal esophagus with PSPW index (r=− 0.251; P= 0.052).
Table 4 Bolus transit and 24-h pH/impedance findings in LTx patients with various esophageal diagnoses based on Chicago Classification v3.0
Normal (n= 14) EGJOOa
(n= 13)
Hyper-contractility
(n=12)
EGJOOa with hyper-
contractility (n= 4)
Hypo-contractility
(n=7)
General characteristics
Age, yearsa 60 (53–63) 59 (54–62) 64 (58–66) 60 (39–66) 57 (35–58)
Female:Male ratio 7:7 5:8 6:6 3:1 5:2
BMI, kg/m2 b 26.4 (23.7–29.2) 26.9 (24.0–29.8) 27.2 (24.2–30.2) 24.4 (22.4–26.3) 27.1 (20.8–33.4)
LTx, n(%) c
Unilateral 6 (43%) 7 (54%) 3 (25%) 0 0
Bilateral 8 (57%) 6 (46%) 9 (75%) 4 (100%) 7 (100%)
Anti-reflux surgery, n(%)c 2 (14%) 0 1 (8%) 0 1 (14%)
Post-LTx complications
Acute rejection, n(%)c 8 (57%) 8 (62%) 9 (75%) 3 (75%) 4 (57%)
o-CLAD, n(%)c 4 (29%) 10 (77%)* 4 (33%) 1 (25%) 4(57%)
Time to o-CLAD, daysa 273 (183–1451) 748 (578–921) 891 (609–1651) 731 672 (411–1492)
Death, n(%)c 0 3 (23%) 0 0 1 (14%)
Bolus transit:
Patients with IBT, n(%)c 8 (57%) 9 (69%) 4 (33%) 1 (25%) 6 (86%)
Swallows with IBT, %a 30 (0–50) 50 (20–90) 10 (0–30) 5 (0–25) 60 (30–100)
24-hr pH/impedance
Total no. events, n a 70 (39–90) 37 (19–45) 42 (13–55) 32 (10–38) 72 (27–76)
Patients with abnormal no.
of events, n(%)c
9/14 (64%) 1/10 (10%)* 2/10 (20%)* 0 3/5 (60%)
Proximal events, n a 16 (9–26) 11 (6–13) 8 (3–22) 3 (2–11) 31 (8–34)
Patients with abnormal no.
of proximal events, n(%)c
5/14 (36%) 1/10 (10%) 3/11 (27%) 0 3/6 (50%)
Total reflux bolus exposure
time, %a
1.5 (0.8–2.3) 0.6 (0.4–0.9)* 0.7 (0.2–1.9) 0.4 (0.3–0.9)* 1.7 (0.7–6.7)
Bolus clearance time, sa 13 (10–14) 11 (7–12) 13 (9–16) 13 (6–16) 17(11–26)
Acid exposure time, %a 3.8 (1.1–7.9) 0.9 (0.4–3.7) 2.0 (0.3–7.2) 1.4 (0.9–2.0) 0.3 (0.1–16.3)
BMI, body mass index; EGJOOa, esophagogastric outflow obstruction alone; IBT, incomplete bolus transit; LTx, lung transplantation; o-CLAD, obstructive chronic lung
allograft dysfunction.
aResults expressed as either median (IQR).
bMean (95% CI).
cCategorical variables.
*Po0.05 compared with normal motility.
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in order to reduce the risk of o-CLAD can only be
recommended. Interestingly in our study, a low PSPW index
was associated with more reflux events reaching the proximal
esophagus. This together with the fact that 70%of LTx patients
have oropharyngeal dysphagia,31,32 with those with “normal”
swallowing in the early postoperative period having improved
long-term survival compared with those with abnormal
swallowing,32 support our hypothesis that abnormal swallow-
ing may play a very important role, through a route different
than aspiration of refluxate in development of o-CLAD.
Our study has limitations. For example, we had no pre-
transplantation data for comparison. This does not detract from
the potentially important clinical observation that aspiration of
swallowed material, particularly in those patients with EGJOOa
may be equally, if not more important than aspiration of
refluxate.17 Second, only 22% of patients were off PPI therapy
during pH/impedance assessment, with the rest split evenly
between once and twice daily PPI; hence analysis focused
mainly on impedance rather than pH data. The distribution of
patients on and off PPI was similar across all patient subgroups
and had no effect on findings. Moreover, following pH/
impedance testing most patients (94%) were on PPI therapy,
and although some patients were on once daily (42%) and
others twice daily (52%) this had no effect on outcome of BOS.
Patient’s post-LTx is on many medications, which cannot be
controlled for. Thus to avoid esophageal interaction with
narcotics, our clinical protocol has evolved to assess patients
~3 months after LTx when they are no longer taking these
medications and are scheduled to return to their local
physicians. Finally, while the relatively high percentage of
patients in our study with manometric achalasia is surprising,
we cannot say if this is a primary or secondary disorder. Aswith
EGJOO, aspiration of swallowed material in these achalasia
patients can be detrimental to the native lung or allograft.
In conclusion, our observations call for increased attention
to abnormal swallowing and impaired clearance of swallowed
material or refluxate, and highlight the importance of perform-
ing HRIM and not just esophageal pH/impedance in LTx
patients. Furthermore, they question the empirical use of acid
suppression, especially in those with normal proximal eso-
phageal reflux, and potentially explain why fundoplication
does not always improve lung function. While treatment of
EGJOOa using, e.g., botox or pneumatic dilatation could be
considered this needs to be carefully balanced with the
potential to augment GERD by decreasing the competency of
the EGJ. For those with impaired clearance, prokinetics could
be considered but the effect of these medications on
esophageal peristalsis is limited. Further carefully designed
and appropriately powered studies are needed to better define
the most appropriate clinical management pathways required
to treat these patients.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ Long-term survival following lung transplantation is lower
than other solid organ transplants usually as a
consequence of the development of o-CLAD.
✓ Aspiration of gastric contents, aided by gastroesophageal
reflux and ineffective esophageal motility, is thought to be a
non-alloimmune cause for the development of o-CLAD;
though evidence supporting this is inconsistent.
WHAT IS NEW HERE
✓ Esophagogastric junction outflow obstruction alone
(EGJOOa), incomplete bolus transit and proximal reflux are
independent predictors of o-CLAD.
✓ Patients with EGJOOa are most likely to develop o-CLAD;
despite exhibiting less gastroesophageal reflux than those
with normal motility.
✓ Poor esophageal clearance documented by abnormal
PSPW index associates with o-CLAD; inversely correlating
with the proportion of reflux events reaching the proximal
esophagus.
TRANSLATIONAL IMPACT
✓ These observations call for increased clinical attention to be
given to abnormal swallowing and impaired clearance of
swallowed material or refluxate, and highlight the
importance of performing high-resolution esophageal
impedance manometry (HRIM) post-lung transplantation,
especially before performing fundoplication.
✓ They also question the empirical use of acid suppression,
especially in those with normal proximal reflux and in the
light that proton pump inhibitors are increasing being
associated with additional risks such as pneumonia and
Clostridium difficile infection.
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